Eli Lilly and Company (NYSE:LLY) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,050 shares of the company’s stock after selling 4,622 shares during the period. Eli Lilly and Company comprises about 0.7% of Snowden Capital Advisors LLC’s holdings, making the stock its 22nd biggest position. Snowden Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $21,655,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. RMR Wealth Builders grew its stake in Eli Lilly and Company by 2.3% in the 4th quarter. RMR Wealth Builders now owns 4,686 shares of the company’s stock valued at $3,618,000 after acquiring an additional 107 shares during the last quarter. Grassi Investment Management lifted its holdings in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company’s stock valued at $61,383,000 after purchasing an additional 225 shares in the last quarter. Elevate Capital Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $262,000. Quad Cities Investment Group LLC raised its position in shares of Eli Lilly and Company by 5.6% during the 4th quarter. Quad Cities Investment Group LLC now owns 399 shares of the company’s stock worth $308,000 after purchasing an additional 21 shares during the last quarter. Finally, Affinity Capital Advisors LLC raised its position in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Affinity Capital Advisors LLC now owns 5,513 shares of the company’s stock worth $4,263,000 after purchasing an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $732.40 on Friday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a market capitalization of $694.12 billion, a price-to-earnings ratio of 62.54, a PEG ratio of 1.40 and a beta of 0.48. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm’s fifty day simple moving average is $799.17 and its 200 day simple moving average is $807.15.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.58 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.82%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on LLY shares. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.37.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.